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increasing the quality of life. A prospective trial to test decision 
making with the model versus a controlled group with standard 
treatment is the next step towards implementation of a decision 
support system for rectal cancer.  
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Modern radiotherapy research is built on well validated biological and 
physical hypotheses which will be tested in the clinical trial.  The trial 
design must enable the investigator to obtain a clear answer to the 
primary trial objective, through clear enunciation of the primary 
hypothesis, the endpoint to be measured and an appropriate 
statistical design to enable the hypothesis to be evaluated in a way 
which is reliable. The extreme heterogeneity of cancer is leading 
some investigators to think that conventional clinical trial 
methodology is outmoded and that fundamentally different 
approaches are required. Individualisation of therapy on the basis of 
tumour genotype, imaging or both is portrayed as the goal of modern 
cancer therapy. Individualisation of radiotherapy occurs in every case 
through the treatment planning process and within clinical trials this 
must be undertaken within the constraints of a prospectively 
optimised and agreed radiotherapy treatment protocol and 
commensurate RT quality assurance process to be delivered before 
and during the trial. Similarly biomarker or imaging based treatment 
allocation or randomisation requires the use of rigorous technical 
delivery of the assay or scan and an agreed method of interpretation 
of the outcome. In phase 1 drug radiation trials, delays while waiting 
for assessment of radiotherapy toxicity risk making such studies too 
slow and relatively early dose escalation and ‘flip-flop’design 
evaluating two novel agents in alternating dose escalation cohorts is 
an efficient design. Multi-stage trial designs can speed up the phase 
II/III evaluation of novel therapies, while enabling early termination 
for futility. The SCOPE-1 trial of the addition of cetuximab to 
chemoradiotherapy for oesophageal cancer is an example. Prospective 
molecular sstratification of patients for intervention trials relevant to 
the specific abnormalities in their tumour can be designed but require 
extensive collaboration and large numbers. Such designs are coming 
into stratified drug trials such as the FOCUS4 study in metastatic 
colorectal cancer and the applicability to radiotherapy studies will be 
discussed.  
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Integration of molecular imaging techniques into therapy selection 
strategies and radiation treatment planning can serve several 
purposes. First, pretreatment assessments can steer decisions about 
radiotherapy modifications or combinations with other modalities. 
Second, biology-based objective functions can be introduced to the 
radiation treatment planning process by co-registration of functional 
imaging with planning CT-scans. Thus, customized heterogeneous dose 
distributions can be generated with escalating doses to tumor areas 
where radiotherapy resistance mechanisms are most prevalent. Third, 
monitoring of temporal and spatial variations in these radiotherapy 
resistance mechanisms early during the treatment can discriminate 
responders from non-responders. With such information available 
shortly after the start of the treatment, modifications can be 
implemented or the radiation treatment plan can be adapted tailing 
the biological response pattern. 
Currently, these strategies are in various phases of clinical testing, 
mostly in single-center studies but more and more also in multi-center 
set-up. Ultimately, this should result in availability for routine clinical 
practice requiring stable production and accessibility of tracers, 
reproducibilty and standardization of imaging and analysis methods 
and general availability of knowledge and expertise. Small studies 
employing adaptive radiotherapy based on functional dynamics and 
early response mechanisms demonstrate promising results. This 
approach is closest to large scale clinical testing with good prospects 
for success. 
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The definition of quality in radiation therapy largely remains poorly 
defined, understood and often confused with the issues of safety.  
While safety and quality are on many levels inseparable, there is a 
clear distinction and there can be delivery of safe treatments 
according to physician prescription in radiation therapy which are of 
insufficient quality to meet the treatment goals.  High quality clinical 
operations can be defined as those which minimize variations and 
uncertainty in patient treatments and result in consistent 
outcomes. In radiation therapy, treatment consists of multiple 
components (consultation, treatment selection, immobilization, 
imaging for planning, contouring, planning, etc.).  Relatively large 
variation and uncertainty in any one of these steps contribute to the 
overall degradation of treatment quality.  The degradation of quality 
results in uncertainty in patient outcomes.  Figure 1 a) shows an 
example distribution of patient treatments.  On one end of the 
spectrum is overdose of critical structures, in middle are the majority 
of patient treatments which result in clinical benefit without 
unexpected side effects,and on the other side of the spectrum is 
under dose of target volumes.  The over dose and under dose is clearly 
bad, but the two regions between clinical benefit and over dose and 
under dose, respectively, have clinical uncertainty. Patients falling in 
these uncertainty regions may or may not have clinical complications 
or poor tumor control. Patients falling in extreme over or under dose 
regions are typically infrequent and these are extreme cases that 
typically are widely publicized.  However, it is unclear how many 
patients fall in the uncertainty regions and potentially have 
compromised outcomes.  It is important to note that the outcomes in 
the uncertainty region are often considered as expected and accepted 
treatment outcomes, though possibly avoidable. 
